Press Releases for December 21, 2016
advertisement
- FDA Approval of Dexcom’s Non-Adjunctive Indication Triggers a New Era in Diabetes Management. The Dexcom G5 Mobile CGM System is the first and only medical device that is FDA-approved for making daily diabetes decisions without painful finger pricks. See also FDA expands indication for continuous glucose monitoring system, first to replace fingerstick testing for diabetes treatment decisions.
- Bionic pancreas system successfully controls blood sugar without risk of hypoglycemia.
- Novo Nordisk Receives FDA Approval of Tresiba® (insulin degludec injection 100 U/mL, 200 U/mL) for Use in Children and Adolescents With Diabetes. See also Tresiba gets FDA approval to treat children with type 1 and type 2 diabetes.
- OneTouch Vibe™ Plus Insulin Pump Earns FDA Approval and Health Canada License and is First Pump Integrated with the Dexcom G5® Mobile Continuous Glucose Monitor.
